(1.School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang Jiangsu, 212013； 2.Zhenjiang Municipal Commission of Population and Family Planning, Zhenjiang Jiangsu 212001, China)
Abstract：Objective: To explore the relationship and clinical significance between the expressions of melatonin receptor MT1 and transcription factor Sp1 in breast carcinoma. Methods： The expressions of MT1 and Sp1 in 90 specimens of breast cancer tissues and 50 specimens of adjacent normal breast tissues were detected by immunohistochemical streptavidin-peroxidase (SP) assay and western blotting. Results：There were significant differences in positive expression rates of MT1 and Sp1 between breast cancer tissues and adjacent normal breast tissues (64.4% vs 22.0%, P<0.01 for MT1, respectively, and 74.4% vs 28.0% P<0.01 for Sp1, respectively).The results of western blotting were in accordance with the results of immunohistochemistry technique. The expressions of MT1 and Sp1 in breast cancer tissues were correlated with TNM stage, tumor invasion and lymphnode metastasis(P<0.05), but not correlated with age of patients, tumor size and histological grade(P>0.05). The MT1 expression positively correlated with Sp1 expression in breast cancer tissues(r= 0.523，P<0.01). Conclusion：MT1 and Sp1 may be involved in the invasion and metastasis of breast cancer. The detection of both two expressions is valuable for judging clinical development and presuming prognosis.
［1］Dubocovich ML, Delagrange P, Krause DN, et al. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G proteincoupled melatonin receptors［J］. Pharmacol Rev, 2010, 62(3):343-380.［2］SanchezBarcelo EJ, Mediavilla MD, Alonso-Gonzalez C, et al. Breast cancer therapy based on melatonin［J］. Recent Pat Endocr Metab Immune Drug Discov, 2012, 6(2):108-116.［3］Collins A, Yuan L, Kiefer TL, et al. Overexpression of the MT1 melatonin receptor in MCF7 human breast cancer cells inhibits mammary tumor formation in nude mice［J］.Cancer Lett, 2003, 189(1):49-57.［4］Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer［J］. Eur J Cancer, 2005, 41 (16) :2438-2448.［5］Maor S, Mayer D, Yarden RI, et al. Estrogen receptor insulinlike growth factorⅠreceptor gene expression in breast tumor cells : involvement of transcription factor Sp1［J］. J Endocrinol, 2006, 191( 3 ) : 605-612.［6］PandiPerumal SR, Trakht I, Srinivasan V, et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways［J］. Prog Neurobiol, 2008, 85(3):335-353. ［7］Ekmekcioglu C. Melaton in receptors in humans: biological role and clinical relevance［J］. Biomed Pharmacother, 2006, 60( 3):97-108.［8］Dillon DC, Easley SE, Asch BB, et a1. Differential expression of highaffinity melatonin receptors (MT1)in normal and malignant human breast tissue［J］. Am J Clin Pathol, 2002, 118(3):451-458.［9］Yuan L, Collins AR, Dai J, et al. MT1 melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells［J］. Mol Cell Endocrinol, 2002, 192(1/2):147-156.［10］Mao L, Yuan L, Slakey LM, et al. Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogenactivated protein kinase signaling pathway［J］. Breast Cancer Res, 2010, 12(6): R107.［11］KedzioraKornatowska K, Szewczyk-Golec K, Czuczejko J, et al. Effect of melatonin on the oxidative stress in erythrocytes of healthy young and elderly subjects［J］. J Pineal Res, 2007, 42(2):153-158.［12］Karasek M, Kowalski AJ, Suzin J, et al.Serum melatonin circadian profiles in women suffering from cervical cancer［J］. J Pineal Res, 2005, 39(1):73-76.［13］Kaczynski J, Cook T, Urrutia R．Sp1and Krüppellike transcription factors［J］. Genome Biol, 2003, 4(2):206．［14］Li L, He S, Sun JM, et al. Gene regulation by Sp1and Sp3［J］. Biochem Cell Biol, 2004, 82( 4 ) : 460-471.［15］Safe S, Abdelrahim M．Sp transcription factor family and its role in cancer［J］. Eur J Cancer, 2005, 41(16) : 2438-2448．［16］Jia Z, Gao Y, Wang L, et al. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity［J］. Cancer Res, 2010, 70(3):1111-1119.［17］Wang L, Guan X, Zhang J, et al. Targeted inhibition of Sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models［J］. Int J Oncol, 2008, 33(1):161-167.［18］王晓冰，彭伟强，易智君，等. 转录因子Sp1在乳腺癌组织中的表达及其预后意义［J］. 癌症，2007，26(9)：996-1000.
2013, Vol. 23 
